Phase 2 Adrenal Clinical Trials
14 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–14 of 14 trials
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled67 locationsNCT06900595
Recruiting
Phase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 2Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.153 enrolled32 locationsNCT07159841
Recruiting
Phase 2
Agnostic Therapy in Rare Solid Tumors
Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Congenital Adrenal Hyperplasia
Neurocrine Biosciences6 enrolled3 locationsNCT07187375
Recruiting
Phase 1Phase 2
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
H. Lundbeck A/S42 enrolled17 locationsNCT05669950
Recruiting
Phase 2
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Adrenal Cortical CarcinomaLocally Advanced Adrenal Cortex CarcinomaStage III Adrenal Cortex Carcinoma+2 more
Emory University21 enrolled2 locationsNCT06006013
Recruiting
Phase 2
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
Adrenal Cortical Carcinoma
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia31 enrolled1 locationNCT07085572
Recruiting
Phase 2
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.150 enrolled9 locationsNCT06712823
Recruiting
Phase 2
Ivonescimab in the Treatment of Multiple Advanced Tumors
Urothelial CarcinomaSarcomaKidney Cancer+16 more
Fudan University400 enrolled1 locationNCT06683846
Recruiting
Phase 2
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Adrenal Cortical CancerAdrenal Cortical CarcinomaAdrenal Cancer
West China Hospital28 enrolled1 locationNCT06831175
Recruiting
Phase 2
NeSST2: The Development of a Noninvasive Short Synacthen Test
Adrenal Suppression
Sheffield Children's NHS Foundation Trust12 enrolled1 locationNCT03514589
Completed
Phase 2
A pilot study of Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases.
Metastatic non-small cell carcinoma to the adrenal glandPrimary Renal Cell Carcinoma
Dr Shankar Siva30 enrolled1 locationACTRN12612000759897